Epidermal growth factor receptor gene copy number, K-ras mutation and pathological response to preoperative cetuximab, 5-FU and radiation therapy in locally advanced rectal cancer. - Wikidata - awgldk - TriplyDB

Epidermal growth factor receptor gene copy number, K-ras mutation and pathological response to preoperative cetuximab, 5-FU and radiation therapy in locally advanced rectal cancer.

Epidermal growth factor receptor gene copy number, K-ras mutation and pathological response to preoperative cetuximab, 5-FU and radiation therapy in locally advanced rectal cancer.

http://www.wikidata.org/entity/Q46190706

about

EGFR/HER-targeted therapeutics in ovarian cancer RAS Mutations Beyond KRAS Exon 2: A Review and Discussion of Clinical Trial Data.LIN28B confers radio-resistance through the posttranscriptional control of KRAS.Trastuzumab Sensitizes Ovarian Cancer Cells to EGFR-targeted Therapeutics.Prognostic role of EGFR gene copy number and KRAS mutation in patients with locally advanced rectal cancer treated with preoperative chemoradiotherapy.The role of capecitabine in locally advanced rectal cancer treatment: an update.Neoadjuvant chemoradiotherapy with or without panitumumab in patients with wild-type KRAS, locally advanced rectal cancer (LARC): a randomized, multicenter, phase II trial SAKK 41/07.Incorporating fertility preservation into the care of young oncology patients.Impact of KRAS, BRAF and PI3KCA mutations in rectal carcinomas treated with neoadjuvant radiochemotherapy and surgery.Phase I/II study of neoadjuvant bevacizumab, erlotinib and 5-fluorouracil with concurrent external beam radiation therapy in locally advanced rectal cancer EGF61 polymorphism predicts complete pathologic response to cetuximab-based chemoradiation independent of KRAS status in locally advanced rectal cancer patients.Phospho-ERK and AKT status, but not KRAS mutation status, are associated with outcomes in rectal cancer treated with chemoradiotherapy.Identification of a biomarker profile associated with resistance to neoadjuvant chemoradiation therapy in rectal cancer Predicting response to EGFR inhibitors in metastatic colorectal cancer: current practice and future directions.Neoadjuvant treatment in rectal cancer: actual status.Oncogenic KRAS impairs EGFR antibodies' efficiency by C/EBPβ-dependent suppression of EGFR expression The current state of targeted agents in rectal cancer.The status of targeted agents in the setting of neoadjuvant radiation therapy in locally advanced rectal cancers.Predictive factors of the response of rectal cancer to neoadjuvant radiochemotherapy.Multidisciplinary treatment of resectable rectal cancer.Cetuximab and chemoradiation for rectal cancer--is the water getting muddy?Locally advanced rectal cancer: a comparison of management strategies.Regulation of homeostasis and oncogenesis in the intestinal epithelium by Ras.Radiotherapy response in microsatellite instability related rectal cancer The multidisciplinary approach to the treatment of rectal cancer: 2015 update.Evolving role of cetuximab in the treatment of colorectal cancer.On biomarkers and pathways in rectal cancer: What's the target?Preoperative radiation therapy with concurrent capecitabine, bevacizumab, and erlotinib for rectal cancer: a phase 1 trial Accomplishments in 2008 in the adjuvant treatment of rectal cancer Impact of KRAS Mutations on Management of Colorectal Carcinoma.The efficacy of adding targeted agents to neoadjuvant therapy for locally advanced rectal cancer patients: a meta-analysis.Chromosomal instability portends superior response of rectal adenocarcinoma to chemoradiation therapy.Phase II study of panitumumab, oxaliplatin, 5-fluorouracil, and concurrent radiotherapy as preoperative treatment in high-risk locally advanced rectal cancer patients (StarPan/STAR-02 Study).Mutations in K-ras and epidermal growth factor receptor expression in Korean patients with stages III and IV colorectal cancer.Phase II Study of Preoperative Treatment with External Radiotherapy Plus Panitumumab in Low-Risk, Locally Advanced Rectal Cancer (RaP Study/STAR-03)

P2860

Q26863231-0DAD4320-F7B0-4955-86BB-54EF98820498 Q30967175-0CD296A8-E32E-4C49-9F3D-0AC8D790AA64 Q33575786-50D72496-F7E4-4903-840C-68E170124F16 Q33816185-58B22B82-2CB8-4320-99FB-84ABB8E1BD6D Q34250130-789452BA-3635-4D3A-A6E0-429D100858BF Q34276823-A5A43768-D924-4B4A-B2B7-6852A40F5877 Q34471583-1275BF72-35A4-49A3-A884-534A0E9DF06D Q34675126-AB418D6B-9313-4813-A287-EB0C74116233 Q34687101-7E0A368B-5A83-4F49-BC55-25FD08F265FB Q34737137-666C0BA4-5BD1-4443-BC5F-AC4EE0458BFE Q35146143-46BE7004-6065-4361-9AE4-5788EC0CAED8 Q35233751-1B95A28C-1396-4437-B683-9FB363315AF4 Q35460703-FF3D1718-38E8-4E6A-A8E0-DE758C3FE335 Q35583889-EF306E07-C26B-4892-9C1F-03E0576A4772 Q35687452-79D4C9CA-3975-4CF3-A23C-0CB209AA1079 Q35882193-EDA0362E-F276-42E0-A954-090B9C512F08 Q35996651-85C60C55-2641-4BDF-BFE6-908CCD92C1D6 Q37015715-DA7BCC12-73A1-4FAC-B719-13124FE237CB Q37132742-BFAC8B81-2304-42BD-8D3B-CB59ED40C691 Q37578503-A3B36C0F-5CF0-4EA6-A6DF-4F86DCC61D1C Q37697800-A05083AD-AC8A-43EF-B991-04D157F32B98 Q37895253-CFC1E479-7F65-46B6-AE23-DAF251E1E984 Q37899488-DEDEF3F4-38F4-4BCE-964E-30CF712F2D0A Q38088639-E2D2F5A7-AC74-40F3-8677-CF7E5A7F4068 Q38272299-58B01285-6D20-443C-BF46-FF6073520E6C Q40014365-405C5652-09BC-44B8-97B0-6C70E54AC0DB Q41170919-876F1542-CE08-4AB8-A4F0-54B4ED1DA92D Q41395104-8043B159-ECA9-4A59-9104-57781173E3D4 Q42002475-73CEBBC9-E8EF-4CAB-B748-A71E7A9AA144 Q42258990-39897797-94C4-4922-84EE-4E2D44F63D00 Q49718931-C5C7BA3B-51A7-4693-A035-CABACB5C5BA5 Q51104404-BCF0C93B-BA25-4ED1-8FE9-37DE2CD1852B Q53239683-21CA481A-48BF-4011-9E14-EB3C03A9E359 Q54378950-52D5A564-2B24-4A6B-957B-BB5EECA0E9C7 Q56357033-D5ECA0A0-7C79-4FA7-A3F0-C7CFAAFA4423

P2860

Epidermal growth factor receptor gene copy number, K-ras mutation and pathological response to preoperative cetuximab, 5-FU and radiation therapy in locally advanced rectal cancer.

http://www.wikidata.org/entity/Q46190706

description

2008 nî lūn-bûn

@nan

2008年の論文

@ja

2008年学术文章

@wuu

2008年学术文章

@zh-cn

2008年学术文章

@zh-hans

2008年学术文章

@zh-my

2008年学术文章

@zh-sg

2008年學術文章

@yue

2008年學術文章

@zh

2008年學術文章

@zh-hant

name

Epidermal growth factor recept ...... ocally advanced rectal cancer.

@en

Epidermal growth factor recept ...... ocally advanced rectal cancer.

@nl

type

label

Epidermal growth factor recept ...... ocally advanced rectal cancer.

@en

Epidermal growth factor recept ...... ocally advanced rectal cancer.

@nl

prefLabel

Epidermal growth factor recept ...... ocally advanced rectal cancer.

@en

Epidermal growth factor recept ...... ocally advanced rectal cancer.

@nl

P1433

Q46190706-AFFF3BF8-778B-4DAE-BE79-57C143B065CE

P1476

Q46190706-CBD12843-66AD-4074-B26C-B8E0C9D93C9A

P2093

Q46190706-0588C027-0F66-4AB7-B2C0-4CD9AE168EB6

Q46190706-200E32AA-E2E0-4B2A-A9EF-7562F45C4C62

Q46190706-3AA8933A-47DD-4F8D-8C92-FE10EC375AEB

Q46190706-4CBA5DDA-3715-404A-9A68-5E7F93DEE18D

Q46190706-85373437-DC4B-41DC-BA51-4407F73AAAE2

Q46190706-A2B9D585-9BB1-429D-AB22-687B168EB09D

Q46190706-B7735106-ACB7-467E-89B2-CE990A60ABC6

Q46190706-CD9EF66C-234A-4F81-B8F0-D6BA24EF463A

Q46190706-E807A7E7-6F95-4843-AFE9-9B5C0C3073E6

Q46190706-F471694D-AE74-4A73-B8CB-698AE81C6CFD

P2860

Q46190706-1CD658B4-F295-4AAB-9C33-7B97138E2DBF

Q46190706-316D8F68-A9C8-4400-BCE4-035F4086F2CE

Q46190706-50A8D324-CADD-4B55-BDF6-AC794CA7C799

Q46190706-6B695F21-8CC6-4357-8AEF-339397781C8B

Q46190706-771DEC54-5C68-42A5-AF35-429212D5879E

Q46190706-7EE24179-447A-477D-8ED3-80B80230B57F

Q46190706-7F9D5A32-5706-49E2-936D-8642114DE16F

Q46190706-81A67EFE-C6DA-4D33-ADA7-E807821EFD52

Q46190706-9D689D89-EE26-460A-97BE-058814FA1F91

Q46190706-AC580DD9-F667-4BBA-AF64-9425F592D221

P304

Q46190706-68CF3908-E31F-4476-B8C8-9BF84247A125

P31

Q46190706-BA819A10-D091-492B-AF73-501E49160DAA

P356

Q46190706-98C3498B-4500-472E-8AF1-438B5FCAA380

P433

Q46190706-2B4F310D-8BC0-464E-A117-A2B1F030886A

P478

Q46190706-83D70774-653A-45A2-800D-16AB45B8DC19

P50

Q46190706-8755B74B-9D83-4575-A442-85CEFC008A54

Q46190706-8D0E10DC-CB87-4732-A051-144D7AABDA6C

Q46190706-A5ED7144-F775-4002-921D-1984E666DC29

Q46190706-ECD7C52C-6D24-4FE9-A4D4-9B86BC787F26

P577

Q46190706-6F734E19-44FE-45F1-9A4D-914C089A5D2C

P698

Q46190706-558A320B-DF34-4C08-B69E-95E45B8659CD

P921

Q46190706-0BA7117E-4E6F-4245-99EE-6EC299E1368D

Q46190706-52BE94F4-72B3-48D3-A873-F1BFA7724A78

P356

P1433

Annals of Oncology

P1476

Epidermal growth factor recept ...... locally advanced rectal cancer

@en

P2093

B Gatteschi

http://www.w3.org/2001/XMLSchema#string

C Bengala

http://www.w3.org/2001/XMLSchema#string

C Dealis

http://www.w3.org/2001/XMLSchema#string

C Sonaglio

http://www.w3.org/2001/XMLSchema#string

F Bertolini

http://www.w3.org/2001/XMLSchema#string

G Luppi

http://www.w3.org/2001/XMLSchema#string

G Sartori

http://www.w3.org/2001/XMLSchema#string

L Losi

http://www.w3.org/2001/XMLSchema#string

N Bigiani

http://www.w3.org/2001/XMLSchema#string

N Malavasi

http://www.w3.org/2001/XMLSchema#string

P2860

Prognostic impact of epidermal growth factor receptor (EGFR) expression on loco-regional recurrence after preoperative radiotherapy in rectal cancer.

Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor.

KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer.

KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab.

Molecular predictors of survival after adjuvant chemotherapy for colon cancer

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry.

The epidermal growth factor receptor pathway: a model for targeted therapy.

PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients.

Sequence-dependent antiproliferative effects of cytotoxic drugs and epidermal growth factor receptor inhibitors.

P304

469-474

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/ANNONC/MDN647

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

20

http://www.w3.org/2001/XMLSchema#string

P50

Roberto D'Amico

Stefania Bettelli

Antonino Maiorana

PierFranco Conte

P577

2008-12-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19095777

http://www.w3.org/2001/XMLSchema#string

P921

radiation therapy